• Home
  •  / Endo International
Endo International

Endo International


$3 B

FY, 2021

Market Capitalization

$68.4 M


Endo International Summary

Company summary

Endo International plc is a global specialty pharmaceutical company focused on improving the lives of patients while creating value. Endo develops, manufactures, markets and distributes quality branded and generic pharmaceutical products as well as over-the-counter medications through our operating companies – Endo Pharmaceuticals, Par Pharmaceutical, Paladin Labs, SOMAR and Litha. Endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from The DuPont Merck Pharmaceutical Company. Since that time, the company has expanded to include the following business segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals and International Pharmaceuticals. Endo’s strategy is to maximize value for our key stakeholders by employing an efficient operating model with focused and disciplined execution that allows us to pursue growth opportunities both organically and through selective acquisitions. Additionally, we are leveraging a research and development model that focuses on lower risk, near-term projects. Our goal is to consistently create value for our shareholders while serving our patients and customers. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, Pennsylvania. We employ approximately 6,000 people worldwide.
Dublin 4, IE | view all locations
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data

LocationsView all

20 locations detected

  • Dublin 4, D HQ


    2nd Floor, Minerva House, Simmonscourt Rd, Ballsbridge

  • Charlotte, NC

    United States

    3241 Woodpark Blvd

  • Charlotte, NC

    United States

    3700 Woodpark Blvd

  • Chestnut Ridge, NY

    United States

    1 Ram Ridge Rd

  • Chestnut Ridge, NY

    United States

    6 Ram Ridge Rd

  • Cranbury Township, NJ

    United States

    7 Clarke Dr, Cranbury

and 14 others

Endo International Financials

Summary financials

Revenue (Q2, 2022)
Gross profit (Q2, 2022)
Net income (Q2, 2022)
Cash (Q2, 2022)
EBIT (Q2, 2022)
Enterprise value

Footer menu